FINWIRES · TerminalLIVE
FINWIRES

$REGN

46 stories mentioning REGNUpdated 3d ago

Every FINWIRES story that references REGN, newest first.

What are analysts saying about REGN?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on REGN?

Sectors

Sector Update: Healthcare Stocks Decline Pre-Bell Monday

Healthcare stocks were declining pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.5% and the iShares Biotechnology ETF (IBB) 0.6% lower.Regeneron Pharmaceuticals (REGN) stock was down more than 11% after the company said two dose levels of fianlimab in combination with cemiplimab, evaluated as a first-line treatment in unresectable locally advanced or metastatic melanoma, failed to meet a primary endpoint in its phase 3 trial.Bio-Rad Laboratories (BIO) has attracted a sizable investment from Elliott Investment Management, which plans to push the life-science tools supplier to improve its lagging stock performance, The Wall Street Journal reported, citing people familiar with the matter. Bio-Rad Laboratories shares were up more than 7% premarket.Boston Scientific (BSX) entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase (JPM) as part of its previously announced $5 billion share buyback authorization, the company said. Boston Scientific also said it invested $1.5 billion for an approximately 34% stake in privately held MiRus. Shares of Boston Scientific were up about 2% pre-bell.

$BIO$BSX$IBB$JPM$REGN$XLV
Sectors

Sector Update: Health Care

Health care stocks were mixed pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.7% and the iShares Biotechnology ETF (IBB) 1.9% higher.Regeneron Pharmaceuticals (REGN) stock was down more than 12% after the company said two dose levels of fianlimab in combination with cemiplimab, evaluated as a first-line treatment in unresectable locally advanced or metastatic melanoma, failed to meet a primary endpoint in its phase 3 trial.

$REGN
Asia Markets

New Drone Incidents in Middle East Keep Tensions High, Nudge US Equity Futures Pre-Bell Lower

US equity futures were lower pre-bell Monday as tensions remain high in the Middle East after the UAE and Saudi Arabia reported fresh drone incidents on Sunday, raising traders' concerns around a return to hostilities in the region.Dow Jones Industrial Average futures were 0.3% lower, S&P 500 futures were down 0.2%, and Nasdaq futures were 0.1% lower.The UAE defense ministry said that a drone attack from the "western border" had caused a fire at a nuclear plant, while Saudi Arabia reported intercepting three drones that entered from the airspace of Iraq.President Donald Trump in a post on Truth Social urged Iran to "get moving" with regard to ending the conflict. "For Iran, the Clock is Ticking, and they better get moving, FAST, or there won't be anything left of them," he said.Among the companies reporting financial results this week are Home Depot (HD), Nvidia (NVDA), Analog Devices (ADI), and Walmart (WMT).Oil prices were lower, with front-month global benchmark North Sea Brent crude down 0.7% at $108.66 per barrel and US West Texas Intermediate crude 0.8% lower at $100.25 per barrel.The May US housing market index, slated for 10 am ET, is seen coming in at 34, unchanged from the prior month, according to estimates compiled by Bloomberg.Cheryl Venable, interim president of the Federal Reserve Bank of Atlanta, is slated to speak on Monday.In other world markets, Japan's Nikkei closed 1% lower, Hong Kong's Hang Seng ended 1.1% lower, and China's Shanghai Composite finished 0.1% lower. Meanwhile, the UK's FTSE 100 was up 0.5%, and Germany's DAX index was 0.8% higher in Europe's early afternoon session.In equities, Dominion Energy (D) shares jumped 15% after the company and NextEra Energy (NEE) said they agreed to combine in an all-stock deal. ServiceNow (NOW) stock was up 5.1% after the company and Experian said they launched a multiyear partnership on autonomous AI agents across various platforms. Baidu (BIDU) shares were up 4.2% after the company posted Q1 non-GAAP earnings and revenue that surpassed analysts' consensus.On the losing side, Tesla (TSLA) stock was down 0.9% after the company reportedly raised prices for several Tesla Model Y variants in the US, media outlets reported Saturday. Regeneron Pharmaceuticals (REGN) shares were 12% lower after the company said its phase 3 skin cancer trial evaluating two dose levels of fianlimab in combination with cemiplimab failed to meet a primary endpoint. NextEra Energy stock was down 1.3% after the merger with Dominion Energy was announced.

Dow JonesNasdaq CompositeS&P 500$ADI$BIDU$D$HD$NEE$NOW$NVDA$REGN$TSLA$WMT
Research

Leerink Partners Downgrades Regeneron Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $641 From $792

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $852.58, according to analysts polled by FactSet.

$REGN
Research

Citigroup Downgrades Regeneron Pharmaceuticals to Neutral From Buy, Adjusts PT to $700 From $900

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $852.58, according to analysts polled by FactSet.

$REGN
Wire

Regeneron Fails to Meet Primary Endpoint in Phase 3 Skin Cancer Trial; Shares Down Pre-Bell

Regeneron Pharmaceuticals (REGN) said late Friday that two dose levels of fianlimab in combination with cemiplimab, evaluated as a first-line treatment in unresectable locally advanced or metastatic melanoma, failed to meet a primary endpoint in its phase 3 trial.The combination demonstrated a numeric 5.1-month improvement in median progression-free survival compared to pembrolizumab monotherapy, but did not reach statistical significance for the primary endpoint, Regeneron said.Regeneron said that detailed results from the trial will be presented at an upcoming medical meeting.A phase 3 head-to-head trial of the high-dose fianlimab combination compared with Opdualag is ongoing, the company added.Shares of the company were down more than 11% in Monday's premarket activity.Price: $616.00, Change: $-82.25, Percent Change: -11.78%

$REGN
Wire

Regeneron's Eylea Franchise on 'Solid Footing' Despite HD Sales Miss in Q1, Oppenheimer Says

Regeneron Pharmaceuticals' (REGN) Q1 results reflected mixed trends, as weaker-than-expected sales of high-dose Eylea weighed on shares, though the broader franchise remains "on solid footing," Oppenheimer said in a note Wednesday.The biotechnology company posted non-GAAP earnings of $9.47 per diluted share, surpassing analyst expectations, but the stock faced downward pressure after Eylea HD recorded $468 million in sales, below the $490 million consensus, the brokerage said.The Eylea franchise got a boost with the US Food and Drug Administration approval of "extended dosing" intervals for HD in wet age-related macular degeneration and diabetic macular edema, according to the note. A decision on a pre-filled syringe is expected in Q2 and Oppenheimer said label expansion for HD could support adoption and help offset market share pressure.Dupixent remains a "key growth driver," supported by "durable demand" and new indications, including chronic spontaneous urticaria and allergic fungal rhinosinusitis, according to the note.Despite competition, the company's outlook is balanced, supported by Dupixent growth, expanding Eylea HD uptake, and expected higher collaboration profits with Sanofi (SNY), the brokerage said.Oppenheimer maintained an outperform rating on Regeneron, with a price target of $865.Shares of Regeneron were up more than 3% in Thursday trading.Price: $707.76, Change: $+21.40, Percent Change: +3.12%

$REGN$SNY
Wire

Raymond James Adjusts Regeneron Pharmaceuticals Price Target to $902 From $910

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.Price: $705.61, Change: $+19.25, Percent Change: +2.80%

$REGN
Wire

Leerink Partners Adjusts Regeneron Pharmaceuticals Price Target to $792 From $873

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.Price: $705.61, Change: $+19.25, Percent Change: +2.80%

$REGN
Wire

Barclays Adjusts Regeneron Pharmaceuticals Price Target to $917 From $923

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.Price: $705.61, Change: $+19.25, Percent Change: +2.80%

$REGN
Wire

Morgan Stanley Adjusts Regeneron Pharmaceuticals PT to $788 From $796

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.Price: $705.61, Change: $+19.25, Percent Change: +2.80%

$REGN
Wire

Goldman Sachs Adjusts Regeneron Pharmaceuticals Price Target to $968 From $967

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.Price: $706.67, Change: $+20.31, Percent Change: +2.96%

$REGN
Wire

Bernstein Adjusts Regeneron Pharmaceuticals PT to $916 From $913

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.Price: $706.12, Change: $+19.76, Percent Change: +2.88%

$REGN
Wire

Cantor Fitzgerald Adjusts Regeneron Pharmaceuticals PT to $800 From $779

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.Price: $706.12, Change: $+19.76, Percent Change: +2.88%

$REGN
Wire

Wells Fargo Adjusts Regeneron Pharmaceuticals PT to $800 From $825

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.Price: $706.12, Change: $+19.76, Percent Change: +2.88%

$REGN
Wire

RBC Trims Price Target on Regeneron Pharmaceuticals to $762 From $779, Keeps Sector Perform Rating

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77 according to analysts polled by FactSet.Price: $695.73, Change: $+9.37, Percent Change: +1.37%

$REGN
Research

Research Alert: CFRA Retains Buy Rating On Shares Of Regeneron Pharmaceuticals, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $846 from $866, based on 16.1x our 2027 EPS estimate, below REGN's 10-year historical forward P/E average. We raise our 2026 EPS estimate to $47.92 from $45.59 and our 2027 EPS estimate to $52.62 from $46.25. Shares of REGN are down nearly 8% today despite the company reporting a strong start to 2026, with Q1 sales up 19% Y/Y and adjusted EPS of $3.57, beating expectations. While REGN acknowledged the temporary interruption in bulk manufacturing at its Ireland facility that negatively impacted the GAAP gross margin, we think the market reaction has been too strong as product availability was not affected and full production is expected to resume by end of Q2. We continue to think 2026 could be a pivotal year, with several key approvals and the initiation of 18 Phase 3 studies. We also positively view the April 23 agreement with the Trump administration, and REGN's commitment to Most Favored Nation pricing while receiving three years of tariff relief on pharmaceutical imports.

$REGN
Wire

Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $779 From $800, Maintains Overweight Rating

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $886.38, according to analysts polled by FactSet.Price: $690.03, Change: $-41.75, Percent Change: -5.70%

$REGN
Research

Research Alert: Regn Posts Strong Q1 Fueled By Dupixent And Eylea Hd Amid Manufacturing Issues

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Regeneron delivered robust Q1 2026 results with total revenues of $3.6B (+19% Y/Y) and non-GAAP EPS of $9.47 (+15% Y/Y), beating consensus estimates. The EYLEA franchise continues to transition from traditional EYLEA to EYLEA HD, with HD sales reaching $468M (+52% Y/Y) while traditional sales declined to $473M (-36% Y/Y) due to biosimilar competition. We view the underlying portfolio strength as encouraging, with Dupixent maintaining exceptional momentum at global sales of $4.9B (+33% Y/Y) and physician unit demand for EYLEA HD increasing 10% sequentially despite inventory normalization. Management expects manufacturing disruptions at the Limerick facility to normalize by the end of Q2, lowering full-year GAAP gross margin guidance to 77%-78%. We believe the company's diversified revenue base and deep pipeline of nearly 50 clinical programs, including the recent Otarmeni approval and advancing Factor XI antibody Phase 3 studies, position REGN well for continued growth despite near-term manufacturing headwinds.

$REGN
Wire

Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $913 From $921, Maintains Outperform Rating

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $886.38, according to analysts polled by FactSet.Price: $738.61, Change: $-27.41, Percent Change: -3.58%

$REGN

Showing 21-40 of 46

Track with the FINWIRES app suite

FolioX
FolioX
Track REGN in your portfolio
WheelAI
WheelAI
Analyze REGN options with the wheel strategy
StockInsider
StockInsider
See market sentiment on REGN